Immunomonitoring of Mold Invasive Infections
Assistance Publique - Hôpitaux de Paris
20 participants
Jul 28, 2025
OBSERVATIONAL
Conditions
Summary
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.
Eligibility
Inclusion Criteria8
- Age ≥ 18 years
- Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium
- Proven or probable according to 2019 EORTC/MGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria
- Within 14 days of IFD diagnosis or
- a refractory state defined by the 2009 MGS/EORT failure criteria (clinical, radiological, or microbiological failure) of a first-line antifungal treatment leading to a change of therapy by the attending physician of the patient
- Patients with aspergillosis or mucormycosis for whom ELISPOTs are developed: Total lymphocyte count > 700/mm3 on the last sample taken
- No opposition to participate to the research
- Affiliated or beneficiary of social security system
Exclusion Criteria2
- Bacterial co-infection in the last 14 days
- Previous treatment with anti-PD1 antibodies
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06285188